Efficacy of Cyberknife for treatment of patients with early non-small cell lung cancer
GUAN Gaowa
KANG Jingbo
ZHANG Xinhong
XU Yunke
FANG Henghu
YAN Xiaomei
ZHAN Xiaoyu
ZHANG Jiayue
Abstract：Objective To discuss the clinical efficacy and toxicity of the early non-small cell lung cancer treated by Cyberknife. Methods Retrospective analysis of 28 patients with early non-small cell lung cancer treated by Cyberknife in our department. A total dose of 28—52 Gy ( median of 42. 2 Gy) was delivered in 3—7 fractions. The median isodose curve was 80﹪ ( 65﹪—87﹪) . Results At a median follow-up of 15 months, the primary tumor local control rate was 96. 4﹪. The one-year disease-free survival rate was 96. 4﹪,and the one-year overall survival rate was 100﹪. Pa-tients with grade Ⅰ—Ⅱ radiation pneumonia were observed in 5 ( 17. 9﹪) , gradeⅠ—Ⅱfatigue in 16 (57. 1﹪), and gradeⅢadverse reactions not observed. Conclusion Cyberknife provide another radical treatment option for patients with early non-small cell lung cancer, which showed higher local control rate and lower adverse reaction.
Keywords：CyberknifeNon-small cell lung cancer ( NSCLC)Radiotherapy
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 78-80 )